Home Cart Sign in  
Chemical Structure| 945526-43-2 Chemical Structure| 945526-43-2

Structure of ISCK03
CAS No.: 945526-43-2

Chemical Structure| 945526-43-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ISCK03 is a cell-permeable c-Kit inhibitor with IC50 < < 2.5 μM in cell-free kinase assays and blocks SCF-induced c-kit and Erk phosphorylation (1 μM causes > 90% inhibition) without any effect on HGF-induced Erk phosphorylation in 501mel melanoma cells, it's a phenyl-imidazolosulfonamide compound.

Synonyms: c-Kit Inhibitor II; N-(4-imidazol-1-yl phenyl)sulfonamide; ISCK03, ISCK-03, ISCK 03.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ISCK03

CAS No. :945526-43-2
Formula : C19H21N3O2S
M.W : 355.45
SMILES Code : O=S(C1=CC=C(C(C)(C)C)C=C1)(NC2=CC=C(N3C=CN=C3)C=C2)=O
Synonyms :
c-Kit Inhibitor II; N-(4-imidazol-1-yl phenyl)sulfonamide; ISCK03, ISCK-03, ISCK 03.
MDL No. :MFCD12031591
InChI Key :XQABBHBFHWHMKF-UHFFFAOYSA-N
Pubchem ID :3792751

Safety of ISCK03

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H319
Precautionary Statements:P305+P351+P338

Related Pathways of ISCK03

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Rat primary neurons 5 µM 1 hour ISCK03, as a C-KIT specific inhibitor, was used to study the role of the Metrnl/C-KIT axis in neuronal ferroptosis. Results showed that ISCK03 treatment significantly reduced p-C-KIT expression and partially reversed the protective effects of r-Metrnl against neuronal ferroptosis. CNS Neurosci Ther. 2025 Feb;31(2):e70286.
LS174T cells 30 µM 2.5 hours Inhibited c-KIT phosphorylation, thereby inhibiting downstream p-ERK1/2 and p-ELK1 as well as CEA expression Cancer Sci. 2021 Feb;112(2):655-667.
Mouse ovarian granulosa cells 5 µM 48 hours Blocked the communication network between granulosa cells and oocytes, decreased pyruvate-free-promoted p-Akt and p-FOXO3a levels, but had no effect on pyruvate-free-promoted mTOR activity Cell Death Dis. 2022 Jan 27;13(1):87.
K562 cells 10 µM or 20 µM 72 hours ISCK03 treatment eliminated the increased survival of KD clones in the absence of serum. Mol Cancer. 2015 Apr 19;14:90.
Mouse ovarian cells 2.5 µM ISCK03 completely blocked TG-, CrCl3- and FeCl3-promoted p-Akt levels but had no effect on MnCl2- and ZnSO4-promoted p-Akt levels. Theranostics. 2023 May 21;13(10):3131-3148.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Subarachnoid hemorrhage (SAH) model Intracerebroventricular injection (i.c.v.) 2.5 mg/kg Single administration 1 h before SAH induction ISCK03, as a C-KIT specific inhibitor, was used to investigate the role of the Metrnl/C-KIT/AMPK/Nrf2 signaling pathway in neuronal ferroptosis after SAH. Results showed that ISCK03 treatment significantly reduced p-C-KIT expression and partially reversed the protective effects of r-Metrnl against neuronal ferroptosis. CNS Neurosci Ther. 2025 Feb;31(2):e70286.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.81mL

0.56mL

0.28mL

14.07mL

2.81mL

1.41mL

28.13mL

5.63mL

2.81mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories